Importantly, these shifts in CB1 and CB2 expression may be dependent on cell-types and therefore could indicate that therapies designed to target these receptors or other ECS proteins in neurons or glial cells may be beneficial for patients with HAND. The gene discussed is CNR1; the disease is HIV-associated neurocognitive disorder.